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Radiation therapy (RT) is responsible for at least 40% of cancer cures, however
treatment resistance remains a clinical problem. There have been recent advances in
understanding the molecular mechanisms of radiation-induced cell death. The type of
cell death after radiation depends on a number of factors including cell type, radiation
dose and quality, oxygen tension, TP53 status, DNA repair capacity, cell cycle phase at
time of radiation exposure, and the microenvironment. Mitotic catastrophe (a pathway
preceding cell death that happens in mitosis or as a consequence of aberrant mitotic
progression) is the primary context of radiation-induced cell death in solid cancers,
although in a small subset of cancers such as haematopoietic malignancies, radiation
results in immediate interphase apoptosis, occurring within hours after exposure. There
is intense therapeutic interest in using stereotactic ablative body radiotherapy (SABR),
a precise, high-dose form of RT given in a small number of fractions, to prime the
immune system for cancer cell killing, but the optimal radiation dose and fractionation
remain unclear. Additionally, promising novel radiosensitisers targeting the cell cycle and
DNA repair pathways are being trialled. In the context of the increasing use of SABR
and such novel agents in the clinic, we provide an updated primer on the major types of
radiation-induced cell death, focussing on their molecular mechanisms, factors affecting
their initiation, and their implications on immunogenicity.
Keywords: radiotherapy, radiation therapy, stereotactic ablative radiotherapy, cell death, immunogenic cell death,
abscopal effect
INTRODUCTION
Radiation therapy (RT) is a major cancer treatment modality and is responsible for at least 40% of
cancer cures (Ringborg et al., 2003), yet treatment resistance remains a clinical problem. A primary
reason for this is the capacity for cancer cells to evade radiation-induced cell death. Treatment
paradigms have traditionally viewed cancer as a cell-autonomous problem of dysregulated
proliferation while side-lining host-tumour interactions, but this dogma has undergone a
remarkable revolution in the last few decades, with increasing appreciation of the tumour stroma
and immune milieu in shaping tumour evolution. Trials of novel radiosensitisers targeting not only
key cell death pathways but also the stromal and immune microenvironment, particularly together
with stereotactic ablative body radiotherapy (SABR), have gained intense interest.
Here, we provide an updated primer on the major types of radiation-induced cell death,
focussing on their molecular mechanisms, factors affecting their initiation, and their implications
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on immunogenicity. We conclude with discussing these aspects
in the context of the increasing use of SABR and novel agents
in the clinic. We point readers interested in further detail to the
excellent referenced reviews.
THE CELL CYCLE AND TYPES OF
RADIATION-INDUCED CELL DEATH
The cell cycle is a highly regulated process occurring in two
major phases: interphase (consisting of the G1, S, and G2
phases) and mitosis (cell division). During interphase, the cell
grows its organelle counts (G1 phase), copies its DNA (S
phase), and reorganises contents in preparation for division (G2
phase). Radiation-induced DNA damage is sensed by the kinases
ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia
and Rad3-related protein (ATR), which activate downstream
proteins to initiate the DNA damage response (reviewed in Maier
et al., 2016). This places the cell into cell cycle arrest, during
which DNA double-strand breaks (DSBs) are repaired mainly
by two pathways: non-homologous end joining (NHEJ) and
homologous recombination (HR). NHEJ is error-prone but active
throughout the cell cycle, while HR is error-free but requires an
undamaged sister chromatid as the repair template, and therefore
is only available in the late S and G2 phases. If damage is too
significant for repair, cell death will occur via one of the types
described below, at varying time points after the initial irradiation
event (interphase or mitotic). In classical radiobiology, cell death
is defined by loss of replicative capacity (i.e., replicative or
reproductive death) and is determined by clonogenic assays.
While this has undoubtedly served the field tremendously, it
ignores the types and effects of cell death, discussed in this review.
Mitotic Catastrophe and Mitotic Death
Mitotic catastrophe is a mechanism for the control of cells
unable to complete mitosis, by the triggering of mitotic arrest
and ultimately regulated cell death (RCD) or senescence. Mitotic
death refers to RCD (usually intrinsic apoptosis) that is driven
by mitotic catastrophe (Galluzzi et al., 2018). Because cells
in mitotic catastrophe are almost always incapable of further
replication, mitotic catastrophe is often confused as a bona
fide cell death type. However, these cells eventually trigger one
of the ‘other’ cell death pathways, or less commonly escape
from this state (Gascoigne and Taylor, 2008; Vakifahmetoglu
et al., 2008). Dysfunctional cell cycle checkpoints, a common
hallmark of cancer cells, allow radiation-damaged cells to enter
mitosis prematurely with misrepaired DNA, leading to mitotic
catastrophe. The exact mechanisms for the initiation of mitotic
catastrophe and the deciding of final cell fate are unclear. Several
attempted divisions can occur before sufficient genetic damage
is accumulated to trigger mitotic death, underlining why solid
tumours often demonstrate delayed responses to RT.
Apoptosis
Apoptosis is a highly regulated form of cell death with
characteristic morphological and molecular features. The
intrinsic (mitochondrial) apoptotic pathway is activated when
the DNA damage repair machinery, with p53 as a central player,
disrupts the balance between pro- and anti-apoptotic factors,
resulting in the release of cytochrome c from the mitochondria
into the cytoplasm to activate the intrinsic pathway-specific
caspase 9 (Eriksson and Stigbrand, 2010). The extrinsic pathway,
in contrast, is initiated by external signalling via binding of
the tumour necrosis factor (TNF) family of ligands to plasma
membrane death receptors, eventually causing downstream
activation of the extrinsic pathway-specific caspase 8. Irradiated
cells can upregulate death receptors, making them susceptible
to death through this pathway (Wu et al., 1997; Chakraborty
et al., 2003; Sheard et al., 2003). The third pathway, the ceramide
pathway, is triggered by radiation-induced activation of acid
sphingomyelinase in the plasma membrane, producing ceramide
via hydrolysis of sphingomyelin. Radiation-induced DNA
damage can also activate mitochondrial ceramide synthase
for de novo synthesis of ceramide. Ceramide acts as a second
messenger in initiating the apoptotic programme, but its
signalling targets are complex (Pettus et al., 2002; Kolesnick
and Fuks, 2003). The intrinsic, extrinsic and ceramide pathways
converge in the activation of caspase 3 and 7, which sets off a
cascade of controlled degradation of cellular components.
Necrosis
Necrosis is an unregulated, chaotic form of cell death, triggered
by unfavourable conditions such as extreme changes in pH,
energy loss, and ion imbalance within the cell and its
microenvironment after irradiation (Kroemer et al., 2009).
Traditionally identified in histological specimens, it is a diagnosis
of exclusion and based on morphology, characterised by a
gain in cellular volume, plasma membrane rupture and spill of
intracellular contents.
Senescence
Senescence refers to permanent cell cycle arrest. Radiation-
induced senescence is triggered by DNA damage and the
induction of the p53 and pRb pathways causing cell cycle
block, but other factors including oxidative stress may also
be relevant triggers in the irradiation context (Sabin and
Anderson, 2011; Li et al., 2018). Importantly, senescent
cells while “dead” in terms of clonogenicity continue to
be viable and metabolically active, over time developing a
specific expression pattern of immunomodulatory factors. This
senescence-associated secretory phenotype is a result of the
extrusion of cytoplasmic chromatin fragments in senescent cells,
which act on the DNA sensing and effector cGAS-STING
pathway to drive expression of interferon and NF-kB elements
(Dou et al., 2017; Gluck et al., 2017).
Autophagy
Autophagy describes the process of sequestrating damaged or old
cytoplasmic organelles within vesicles for lysosomal degradation
in response to cellular stress. It is usually a cytoprotective process,
but autophagic cell death occurs when the autophagic response
is excessive (Kroemer and Levine, 2008). The autophagic
machinery is a highly regulated pathway involving the ATG
genes and is known to be triggered by irradiation, likely via
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the endoplasmic stress module and mTOR pathway, although
the exact mechanisms are unclear (Tam et al., 2017). Autophagy
observed after irradiation may be a mechanism of treatment
resistance or of cell death, being likely context-dependent (Levy
et al., 2017; Dikic and Elazar, 2018).
Other Types of Cell Death
More recently, forms of RCD have been identified in response to
irradiation, including necroptosis and ferroptosis, although the
extent to which these occur in vivo are uncertain (Gong et al.,
2019; Lang et al., 2019; Lei et al., 2019). Necroptosis has similar
morphological appearances to necrosis, but is regulated. It can
be activated by death receptors, but signalling is transduced via
caspase-independent pathways converging on RIPK3 and MLKL.
Ferroptosis is a type of cell death triggered by the accumulation
of lipid peroxides as the lethal event due to decreased degradation
by glutathione peroxidase (GPX4). With irradiation, this is shown
to happen via ATM, which represses the cystene-glutamate
antiporter system xc-, resulting in decreased glutathione, a
co-factor for GPX4 (Lang et al., 2019).
FACTORS AFFECTING TYPE OF CELL
DEATH
Cell-Intrinsic Factors
The type of cell death after irradiation depends on a number
of factors, with many remaining uncertainties. Cell type is a
key determinant. In a subset of tumours such as haematopoietic
malignancies (Radford et al., 1994; Jonathan et al., 1999),
radiation results in immediate interphase apoptosis. In the
majority of solid tumours however, mitotic catastrophe is the
most frequent context of radiation-induced cell death (Eriksson
and Stigbrand, 2010), whereas normal tissues commonly undergo
senescence after irradiation (Nguyen et al., 2018).
The importance of cell type could be related to the cellular
status and function of p53 and ATM. p53 is a key regulator of
apoptosis and senescence. Intact p53 is required for interphase
apoptosis (Fridman and Lowe, 2003), while disruptive TP53
mutations are associated with increased radioresistance via the
inhibition of senescence (Skinner et al., 2012). As most tumour
cells have lost normal p53 function or inactivated its downstream
pathways, the G1/S checkpoint is impaired and DNA damage
repair is consequently dependent on ATR/Chk1-mediated intra-S
and G2/M arrest (Soussi and Beroud, 2001; Brady et al., 2011;
Dillon et al., 2014). Thus, irradiated cells with inactivated p53 will
enter mitosis with unrepaired DNA damage, resulting in mitotic
catastrophe rather than immediate apoptosis or senescence
(Ianzini et al., 2006). While manipulation of p21 or p53 levels may
dramatically alter the kinetics of cell death after irradiation, it may
not always correlate with the overall loss of replicative capacity
(Wouters et al., 1997; Brown and Wouters, 1999). Similarly,
ATM impacts cell death by regulating apoptosis, autophagy, and
possibly necroptosis (Liang et al., 2013; Tripathi et al., 2013;
Chen et al., 2015) (reviewed in Wu et al., 2017), but it is
not clear yet how ATM may affect the decision between these
types of cell death.
The phase of the cell cycle in which irradiation occurs
also influences timing and type of cell death. Studies have
demonstrated cells irradiated in G1 phase divide more times
and survive longer before undergoing apoptosis compared to
cells irradiated in G2 phase, while cells irradiated in mid-to-late
S phase died without undergoing mitosis. Post-mitotic apoptosis
however appeared to be stochastic and variable between cell lines
(Forrester et al., 1999; Endlich et al., 2000).
Radiation Factors
It may be tempting to speculate that ablative doses incline
cells to a different type of cell death compared to conventional
doses per fraction, but whether this occurs as a direct effect of
irradiation is uncertain. The complexities of establishing this link
surround dissecting the effect of dose per fraction from biological
effective dose (BED), and accounting for temporal confounding
by repopulation and cell death dynamics. Worth noting here is
that the induction of sufficient damage to non-nuclear cellular
components to evoke upfront necrosis may require clinically-
irrelevant high doses (Warters et al., 1978). Nonetheless, the rate
of apoptotic events after irradiation can be proportional to the
number of fractions given, in line with the reassortment principle
(cells cycling inter-fraction into states predisposed for interphase
apoptosis) (Verheij and Bartelink, 2000).
Radiation quality may also affect mode of cell death. High
linear energy transfer (LET) radiation such as alpha particles has
been shown to result in enhanced chromosome rearrangements
and reproductive death (Franken et al., 2011), due to both the
complexity and absolute number of DNA damage clusters (Pinto
et al., 2005; Obe et al., 2010).
Microenvironment Factors
The above factors are strongly influenced by the cellular
microenvironment. In brief, oxygen tension modulates cell death
after irradiation, with a reduction in chromosomal aberrations
and reproductive capacity of cells irradiated under hypoxic
conditions. This is presumed due to kinetic competition between
the oxygen ‘fixation’ of DNA damage and chemical repair
processes (reviewed in Stewart et al., 2011). Under the hypoxic,
nutrient-deprived conditions in vivo, cell death will be influenced
both by the chemical properties of oxygen fixation and indirect
effects of hypoxia on cellular processes including cell metabolism,
DNA repair, and hypoxia inducible factor (HIF)-related survival
mechanisms (Harris, 2002). An acidic microenvironment and
serum deprivation also suppress the progression of cells to
apoptosis and the formation of micronuclei after irradiation
(Paglin et al., 1997; Park et al., 2000).
RADIATION-INDUCED IMMUNOGENIC
CELL DEATH
The observation that an intact host immune system improves the
tumour control probability of RT, first made in 1979 (Stone et al.,
1979), suggests that the anti-tumour effects of RT must extend
beyond its direct effects on cancer cells. Over the last decade,
the concept of immunogenic cell death (ICD) has emerged to
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redefine cancer cell death from an immune-functional aspect,
whereby the dying cell through peri-mortem processes is able to
evoke anti-tumour adaptive immune responses (Ma et al., 2010;
Kepp et al., 2014).
Defining ICD
Historically, necrosis has been traditionally thought to be
immunogenic (Scaffidi et al., 2002; Sancho et al., 2009),
while apoptosis has been viewed as immunologically
silent or even tolerogenic (Voll et al., 1997; Krysko and
Vandenabeele, 2010). This relationship is an oversimplification.
Apoptosis (Casares et al., 2005; Obeid et al., 2007b),
necrosis (Scaffidi et al., 2002; Sancho et al., 2009), and
autophagy (Michaud et al., 2011; Ko et al., 2014), have all
been demonstrated to be capable of inducing immunogenic
responses, while necrosis can in fact contribute to a chronic
inflammatory microenvironment that is protumourigenic and
immunosuppressive (Vakkila and Lotze, 2004).
The current framework for understanding ICD disengages
from the traditional forms of cell death and requires two
components: the exposure of danger signals, termed damage-
associated molecular patterns (DAMPs), from the dying cell to
alert antigen presenting cells (APCs), which include dendritic
cells (DCs); and an antigenic epitope to be cross-presented by
APCs for training of T cells (Galluzzi et al., 2017).
Observations That RT Can Induce ICD
Bona fide ICD induced by RT has been directly demonstrated
with in vivo vaccination assays in mouse models (Apetoh et al.,
2007a; Obeid et al., 2007a; Gorin et al., 2014). A strong body of
work now corroborate these landmark findings across different
murine and human cell lines using surrogate measures (Deng
et al., 2014; Gameiro et al., 2014; Golden et al., 2014; Ko et al.,
2014; Lim et al., 2014). Radiation-induced ICD can also be
implied from a growing number of pre-clinical and clinical
studies combining RT with immunotherapy showing improved
systemic tumour responses (reviewed in Deloch et al., 2016;
Grassberger et al., 2019). Although the link is indirect, the release
of DAMPs and antigenic determinants to evoke cancer-specific
immunity in these studies are thought to be at least partially
mediated through radiation-induced ICD. Other important trials
testing RT for this role have yielded negative results for yet-
uncertain reasons (Kwon et al., 2014; Voorwerk et al., 2019),
suggesting that while the phenomenon of radiation-induced ICD
is real, its desired clinical impact is a highly selective event.
Mechanisms of Radiation-Induced ICD
Our understanding of the molecular mechanisms of radiation-
induced ICD and the determinants for their efficient triggering
are in its nascency. Calreticulin, HMGB1, and ATP, the
classically described DAMPs, act on CD91, TLR4, and
purinergic receptors on DCs respectively, to attract, activate,
and promote phagocytosis of cellular corpses by DCs (Ma et al.,
2010). Calreticulin, an endoplasmic reticulum chaperone, is
translocated to the cell surface as part of the unfolded protein
response in stressed cells as a pre-apoptotic event (Obeid et al.,
2007b). HMGB1 is a nuclear chromatin-binding protein that
is released on necrosis (Scaffidi et al., 2002; Apetoh et al.,
2007b). Unlike HMGB1 where passive release can occur,
optimal secretion of ATP in radiation-induced ICD is active
and dependent on intact pre-mortem autophagic machinery for
the accumulation of ATP within autolysosomes (Michaud et al.,
2011; Ko et al., 2014). A host of other DAMPs have since been
identified, including cytosolic double stranded DNA (dsDNA),
the heat shock proteins 70 kDa (HSP70) and 90 kDa (HSP90),
F-actin, and interleukin-33 (reviewed in Krysko et al., 2012;
Galluzzi et al., 2017).
Cytosolic dsDNA and the cGAS-STING axis have recently
emerged as subjects of intense therapeutic interest. dsDNA
is released from either the mitochondria and/or nucleus of
irradiated cells into the cytoplasm and binds to its sensor
cGAS, producing the cyclic dinucleotide cGAMP. Micronuclei
that accumulate when irradiated cells progress through mitosis
with radiation-induced DSBs also constitute a source of dsDNA
(Harding et al., 2017). cGAMP ligates with the adaptor protein
STING to ultimately upregulate the expression of type I
interferon, an important immunomodulatory cytokine (Burdette
and Vance, 2013; Paludan and Bowie, 2013). Importantly,
dsDNA does not need to activate STING in a cell-intrinsic
fashion, but dsDNA or cGAMP can be released upon ICD
and taken up by myeloid cells, including DCs, to activate
STING within those cells (Deng et al., 2014; Diamond et al.,
2018; Schadt et al., 2019). This axis can be shut down by
ablative radiation doses due to the simultaneous induction
of the exonuclease TREX1, which degrades cytosolic dsDNA
(Vanpouille-Box et al., 2017). While this mechanism explains the
negative impact of ablative radiation doses on abscopal responses
in a murine mammary carcinoma model (Dewan et al., 2009),
the observation is not consistently held up in non-abscopal
readouts of tumour immunity, suggesting that other factors may
be involved in this regulation (Burnette et al., 2011; Deng et al.,
2014; Schadt et al., 2019). On the other hand, generation of
DAMPs such as ATP and HMGB1 appears to be proportional
to radiation doses of up to 100 Gy in vitro (Gameiro et al.,
2014), but whether this translates to increased immunogenicity
in vivo is unknown.
On the antigenicity side, RT increases the processing and
MHC-I-restricted presentation of surface antigens in a cell-
autonomous manner, at least partially via the mTOR pathway
(Santin et al., 1997; Verbrugge et al., 2014). More provocatively,
as a result of altered transcriptional activity and antigen
processing, irradiated tumour cells in vitro demonstrate a
diversification of epitope repertoire presented on MHC-I (Reits
et al., 2006). A recent clinical trial combining RT with immune
checkpoint blockade reported a patient case with expansion of T
cell clones against a radiation-induced neoantigen, serving as the
first in-human proof of this concept (Formenti et al., 2018).
DISCUSSION AND CLINICAL
RELEVANCE
Increasingly, our appreciation of the anti-tumour effects of
RT extends beyond a DNA and cancer cell-centric perspective
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FIGURE 1 | The anti-tumour activity of radiation therapy (RT) is multi-faceted.
Tumour irradiation induces both direct and indirect effects in controlling the
tumour. Direct effects are the result of significant radiation-induced DNA
damage in cancer cells leading to their death, which may occur at various
time points after the initial irradiation event. Radiation therapy (RT) also exerts
anti-tumour activity via indirect effects, which include, but are not limited to,
injury of tumour vasculature and priming of host anti-tumour immune
responses. A range of factors influence the triggering and magnitude of these
effects, broadly falling into cell-intrinsic, radiation, and microenvironment
factors. A deeper knowledge of the underpinning mechanisms and their
interplay will reveal opportunities for enhancing the overall anti-tumour activity
of RT. ATM, ataxia-telangiectasia mutated. DAMP, danger
associated-molecular pattern.
(Figure 1). The need to better understand the molecular
pathways of radiation-induced cell death is even more important
in light of recent technological advances in the safe delivery
of RT and the increasing use of novel agents in clinic. SABR
is progressively adopted into routine clinical practice with a
growing number of studies backing its remarkable efficacy,
greater than predicted by a simple extrapolation from lower
doses per fraction. For example, it has been shown to double
median survival for oligometastatic disease (Palma et al., 2019)
and more than double the response rate to immunotherapy
(Formenti et al., 2018; Theelen et al., 2019), leading to the
hypothesis that the biology of tumour response to irradiation is
different when given high dose per fraction. Theoretically, SABR
would induce DNA damage that was more difficult to repair
and decrease tumour cell repopulation due to reduced overall
treatment time, albeit with a cost from decreased inter-fraction
cellular reassortment and reoxygenation. There is currently
insufficient data to confidently propose a model by which SABR
achieves such high efficacy (Moding et al., 2016; Song et al.,
2019). Indeed, some authors argue that the improved local
control seen with SABR purely results from a higher dose
(Brown et al., 2013, 2014).
Others posit that SABR has additional indirect effects on
cancer cells. Significant tumour vascular injury has been shown
to result from SABR, leading to hypoxic cancer cell death
DEFINITIONS
Radiation therapy terms:
Fraction – single treatment session into which the overall radiation therapy
course is broken down.
Stereotactic ablative body radiotherapy/stereotactic body radiation
therapy (SABR/SBRT) – precise, high-dose radiation therapy given in a small
number of fractions.
Abscopal effect – regression of a tumour lesion distant to the radiation field.
Oligometastatic – Stage IV (distant spread) but with a limited number of
metastases (usually less than five).
Linear energy transfer (LET) – measure of radiation quality, describing the
pattern of energy deposition by the radiation.
Biological effective dose (BED) – an expression of total dose for
comparison of biological effects between radiation dose-fractionation
regimens.
Reassortment – the redistribution of cells previously in radioresistant phases
into more radiosensitive phases after each radiation fraction.
Oxygen fixation – the making permanent of DNA damage induced by
radiation, via the formation of irreparable peroxyl radicals.
several days after irradiation (Song et al., 2019). Interestingly, the
ceramide apoptotic pathway in the tumour vascular endothelium,
activated with ablative radiation doses, is thought to be
especially important (Garcia-Barros et al., 2003; Rao et al.,
2014). These results, however, have been directly challenged
in other models (Moding et al., 2015), while others contend
that hypoxia induced by SABR in fact inhibits its efficacy
(Carlson et al., 2011).
The other reason measurements of radiation-induced cancer
cell death in vitro fail to represent the extent of clinically
observed responses is due to host immune responses (Golden
et al., 2012; Haikerwal et al., 2015). For example, inhibition
of the pro-survival autophagy machinery radiosensitises cell
kill in vitro, but in fact impairs radiation tumour control
in immunocompetent mice due to loss of autophagy-
dependent ATP release as an immune adjuvant (Ko et al.,
2014). As such, a pressing question is the impact of radiation
dose-fractionation on cell death pathways, especially those
related to ICD. Studying fractionated regimens in the pre-
clinical setting is complicated because of the physiologically
artificial context and logistical difficulties of irradiating
animals in vivo over an extended number of fractions.
Pre-clinical studies therefore typically employ moderately
hypofractionated or ablative regimens (Demaria and Formenti,
2012; Deloch et al., 2016), potentially biassing the commonly-
held hypothesis that such regimens are better inducers
of ICD.
Finally, greater understanding of the mechanisms of cell
death will enable the application of novel radiosensitisers
(Moding et al., 2016). For example, the dependence of
many cancer cells specifically on the G2/M checkpoint
has led to the development of agents that target this
checkpoint, particularly Chk1, Wee1, ATM, and ATR
(Dillon et al., 2014). Hypoxia-modifying therapy might
prevent HIF-mediated revascularisation, recurrence,
and metastasis (Moding et al., 2016). Additionally,
targeting previously under-appreciated cell death types
such as ferroptosis may support the combination of RT
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and immunotherapy (Lang et al., 2019). Alongside these
developments, biomarker driven studies must not be neglected
to help guide patient selection.
CONCLUSION
Cancer cells undergo a range of interphase and mitotic
death after irradiation via direct and indirect effects of RT.
An increased understanding of the molecular mechanisms of
radiation-induced cell death will reveal novel opportunities for
improving the overall anti-tumour efficacy of RT.
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